share_log

Johnson & Johnson | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

SEC announcement ·  Apr 5 17:32
Summary by Moomoo AI
Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Shockwave Medical, Inc. for $335 per share in cash, amounting to an enterprise value of approximately $13.1 billion, including cash acquired. The acquisition, approved by both companies' boards of directors, is expected to close by mid-year 2024, subject to customary closing conditions and regulatory approvals. This strategic move will enhance J&J's MedTech division, particularly in the cardiovascular intervention segment, and is expected to be accretive to operating margin for both J&J and its MedTech division. Shockwave Medical is recognized for its innovative intravascular lithotripsy (IVL) technology, used in the treatment of calcified coronary and peripheral artery disease. The acquisition follows J&J's recent purchases of Abiomed...Show More
Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Shockwave Medical, Inc. for $335 per share in cash, amounting to an enterprise value of approximately $13.1 billion, including cash acquired. The acquisition, approved by both companies' boards of directors, is expected to close by mid-year 2024, subject to customary closing conditions and regulatory approvals. This strategic move will enhance J&J's MedTech division, particularly in the cardiovascular intervention segment, and is expected to be accretive to operating margin for both J&J and its MedTech division. Shockwave Medical is recognized for its innovative intravascular lithotripsy (IVL) technology, used in the treatment of calcified coronary and peripheral artery disease. The acquisition follows J&J's recent purchases of Abiomed and Laminar, further solidifying its position in cardiovascular intervention. Post-acquisition, Shockwave will operate as a business unit within J&J MedTech, with financials reported within J&J MedTech's Cardiovascular portfolio. The transaction is anticipated to accelerate revenue growth for both entities and expand J&J's MedTech cardiovascular portfolio into high-growth segments. The acquisition is funded through a combination of cash on hand and debt, with J&J expecting to maintain a strong balance sheet.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more